Form 4: Neogenomics Director Gunn Acquires Shares and Stock Options

Director Neil Gunn reports acquisition of Neogenomics stock options and restricted stock units.

Summary

• On June 1, 2024, Neil Gunn, a director of Neogenomics Inc., acquired stock options to purchase 8,672 shares of common stock at an exercise price of $13.71, expiring on June 1, 2034.
• Gunn also acquired 12,254 restricted stock units, which vest on June 1, 2025.
• Following these transactions, Gunn directly owns 8,353 stock options (exercise price $14.82, expiring August 10, 2033), 11,336 restricted stock units, 8,672 new stock options and 12,254 new restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock transactions by a company director. The acquisition of shares and options could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of stock options and restricted stock units by a director may indicate confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the acquisition of stock options and restricted stock units suggests a potential belief in the company's long-term prospects.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as insider ownership is often viewed favorably.

Key Dates